Alimera Sciences, Inc. (ALIM)
| Market Cap | 65.74M |
| Revenue (ttm) | 50.82M |
| Net Income (ttm) | -5.34M |
| Shares Out | 5.12M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | 161.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $9.67 |
| Previous Close | $9.34 |
| Change ($) | 0.33 |
| Change (%) | 3.53% |
| Day's Open | 9.41 |
| Day's Range | 9.39 - 9.75 |
| Day's Volume | 10,789 |
| 52-Week Range | 3.82 - 12.25 |
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription oph...
On Wednesday, April 28, Alimera Sciences (NASDAQ:ALIM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence Amid required stay-at-home orders, many have paused or canceled doctor's appointments over the past 12 months. Rece...
ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic...
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...
Fourth Quarter Highlights:
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic ...
Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...
Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commerciali...
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription opht...
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...
ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis ...
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...
ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q3 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 75.51% and 16.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the manageme...
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalm...
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalm...
ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription o...
ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ILUVIEN receives pricing and reimbursement approvals for both diabet...
ATLANTA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi...
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi...
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.
Second Quarter and Recent Company Highlights:
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
A randomized, controlled , multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription o...
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of reti...
ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments f...
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2019 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Company continues to execute on its international expansion strategy
ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the managem...
ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the managem...
ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments fo...
About ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician o... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Apr 22, 2010 |
| CEO Richard Eiswirth | Employees 130 |
| Stock Exchange NASDAQ | Ticker Symbol ALIM |
Financial Performance
In 2020, ALIM's revenue was $50.82 million, a decrease of -5.79% compared to the previous year's $53.94 million. Losses were -$5.34 million, -48.87% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 16.38, which is an increase of 69.39% from the latest price.